Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus | 7 | 2019 | 45 | 2.300 |
Why?
|
| Pericytes | 4 | 2019 | 21 | 1.930 |
Why?
|
| Cytomegalovirus Infections | 4 | 2019 | 28 | 1.510 |
Why?
|
| Kidney Glomerulus | 3 | 2019 | 86 | 1.200 |
Why?
|
| Herpesvirus 8, Human | 5 | 2011 | 25 | 1.090 |
Why?
|
| Sarcoma, Kaposi | 4 | 2011 | 23 | 1.060 |
Why?
|
| Kidney Diseases | 2 | 2019 | 172 | 1.030 |
Why?
|
| Vaccination | 2 | 2025 | 355 | 0.970 |
Why?
|
| Vaginosis, Bacterial | 2 | 2016 | 8 | 0.850 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2025 | 117 | 0.850 |
Why?
|
| Host-Pathogen Interactions | 2 | 2019 | 209 | 0.840 |
Why?
|
| Cytokines | 6 | 2019 | 678 | 0.780 |
Why?
|
| Papillomavirus Vaccines | 1 | 2025 | 174 | 0.730 |
Why?
|
| Virus Replication | 3 | 2019 | 318 | 0.710 |
Why?
|
| Mesangial Cells | 2 | 2019 | 9 | 0.680 |
Why?
|
| Podocytes | 2 | 2018 | 37 | 0.650 |
Why?
|
| Papillomavirus Infections | 1 | 2025 | 376 | 0.640 |
Why?
|
| Placenta | 2 | 2019 | 117 | 0.630 |
Why?
|
| BK Virus | 1 | 2019 | 4 | 0.610 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 706 | 0.610 |
Why?
|
| Polyomavirus Infections | 1 | 2019 | 18 | 0.610 |
Why?
|
| Trophoblasts | 2 | 2020 | 33 | 0.570 |
Why?
|
| 5' Untranslated Regions | 1 | 2018 | 22 | 0.550 |
Why?
|
| Chorionic Villi | 1 | 2017 | 5 | 0.540 |
Why?
|
| Postoperative Complications | 1 | 2019 | 263 | 0.520 |
Why?
|
| Blood-Retinal Barrier | 1 | 2017 | 11 | 0.520 |
Why?
|
| Eye Diseases | 1 | 2017 | 29 | 0.500 |
Why?
|
| Brain | 3 | 2015 | 1472 | 0.500 |
Why?
|
| Retina | 2 | 2019 | 289 | 0.490 |
Why?
|
| Skin Neoplasms | 2 | 2023 | 178 | 0.470 |
Why?
|
| Fibroblasts | 1 | 2017 | 281 | 0.470 |
Why?
|
| Tennessee | 2 | 2025 | 93 | 0.460 |
Why?
|
| Humans | 26 | 2025 | 43102 | 0.450 |
Why?
|
| Cells, Cultured | 5 | 2017 | 1621 | 0.450 |
Why?
|
| Blood-Brain Barrier | 2 | 2013 | 173 | 0.410 |
Why?
|
| Genome, Viral | 3 | 2009 | 119 | 0.400 |
Why?
|
| Pregnancy | 5 | 2025 | 1772 | 0.380 |
Why?
|
| Up-Regulation | 2 | 2012 | 536 | 0.380 |
Why?
|
| Gardnerella vaginalis | 1 | 2011 | 2 | 0.370 |
Why?
|
| Vagina | 1 | 2011 | 89 | 0.350 |
Why?
|
| Down-Regulation | 2 | 2011 | 456 | 0.350 |
Why?
|
| Calcium-Binding Proteins | 1 | 2011 | 81 | 0.340 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2011 | 78 | 0.340 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 140 | 0.340 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 165 | 0.320 |
Why?
|
| HIV-1 | 1 | 2016 | 755 | 0.310 |
Why?
|
| Galectin 3 | 1 | 2009 | 30 | 0.310 |
Why?
|
| Multigene Family | 1 | 2009 | 105 | 0.300 |
Why?
|
| Epithelial Cells | 1 | 2011 | 434 | 0.280 |
Why?
|
| Kidney Transplantation | 2 | 2019 | 101 | 0.270 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2018 | 196 | 0.270 |
Why?
|
| Female | 9 | 2025 | 24698 | 0.250 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2025 | 3 | 0.240 |
Why?
|
| Phylogeny | 2 | 2009 | 769 | 0.240 |
Why?
|
| Influenza Vaccines | 1 | 2025 | 58 | 0.220 |
Why?
|
| Prenatal Care | 1 | 2025 | 93 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 968 | 0.220 |
Why?
|
| Young Adult | 2 | 2025 | 5080 | 0.210 |
Why?
|
| Particulate Matter | 1 | 2025 | 83 | 0.210 |
Why?
|
| Endothelial Cells | 3 | 2013 | 329 | 0.210 |
Why?
|
| Adolescent | 2 | 2025 | 6081 | 0.210 |
Why?
|
| Endothelium, Vascular | 2 | 2019 | 263 | 0.200 |
Why?
|
| Air Pollutants | 1 | 2025 | 130 | 0.200 |
Why?
|
| Fibronectins | 2 | 2015 | 69 | 0.190 |
Why?
|
| Environmental Exposure | 1 | 2025 | 256 | 0.190 |
Why?
|
| Adult | 3 | 2025 | 13872 | 0.190 |
Why?
|
| Melanoma | 1 | 2023 | 110 | 0.180 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 934 | 0.180 |
Why?
|
| Rural Population | 1 | 2025 | 373 | 0.180 |
Why?
|
| HIV Infections | 1 | 2016 | 2586 | 0.170 |
Why?
|
| Animals | 6 | 2025 | 16992 | 0.170 |
Why?
|
| Decidua | 1 | 2020 | 9 | 0.170 |
Why?
|
| Amnion | 1 | 2020 | 16 | 0.170 |
Why?
|
| Streptococcus | 1 | 2020 | 18 | 0.170 |
Why?
|
| Stromal Cells | 1 | 2020 | 55 | 0.160 |
Why?
|
| Streptococcal Infections | 1 | 2020 | 37 | 0.160 |
Why?
|
| Middle Aged | 2 | 2025 | 12222 | 0.160 |
Why?
|
| Virus Activation | 1 | 2019 | 38 | 0.150 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2015 | 113 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 652 | 0.140 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 101 | 0.140 |
Why?
|
| Interferon-beta | 1 | 2018 | 9 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 989 | 0.140 |
Why?
|
| Chemokine CCL5 | 1 | 2018 | 41 | 0.140 |
Why?
|
| Coculture Techniques | 1 | 2017 | 109 | 0.130 |
Why?
|
| Neurons | 2 | 2015 | 1263 | 0.130 |
Why?
|
| Vero Cells | 1 | 2017 | 112 | 0.130 |
Why?
|
| Macrophages | 1 | 2020 | 529 | 0.120 |
Why?
|
| Causality | 1 | 2016 | 45 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2019 | 863 | 0.120 |
Why?
|
| Inflammation | 1 | 2020 | 758 | 0.110 |
Why?
|
| Antigens | 1 | 2015 | 59 | 0.110 |
Why?
|
| Proteoglycans | 1 | 2015 | 49 | 0.110 |
Why?
|
| Vimentin | 1 | 2015 | 44 | 0.110 |
Why?
|
| Visual Pathways | 1 | 2015 | 40 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 83 | 0.110 |
Why?
|
| Green Fluorescent Proteins | 1 | 2015 | 209 | 0.110 |
Why?
|
| Neuroglia | 1 | 2015 | 133 | 0.100 |
Why?
|
| Cerebrospinal Fluid | 1 | 2013 | 20 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 139 | 0.100 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 33 | 0.100 |
Why?
|
| Genes, Viral | 3 | 2009 | 61 | 0.100 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 2676 | 0.100 |
Why?
|
| Virulence | 2 | 2011 | 246 | 0.100 |
Why?
|
| Steroid Hydroxylases | 1 | 2011 | 3 | 0.090 |
Why?
|
| Molecular Sequence Data | 4 | 2009 | 1542 | 0.090 |
Why?
|
| Receptors, Chemokine | 2 | 2002 | 72 | 0.090 |
Why?
|
| Astrocytes | 1 | 2013 | 244 | 0.090 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 51 | 0.090 |
Why?
|
| Tropoelastin | 1 | 2011 | 14 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1271 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 160 | 0.090 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 224 | 0.090 |
Why?
|
| Sequence Alignment | 2 | 2009 | 272 | 0.090 |
Why?
|
| Amino Acid Sequence | 3 | 2009 | 1180 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2013 | 269 | 0.080 |
Why?
|
| Risk Factors | 1 | 2019 | 3994 | 0.080 |
Why?
|
| Microcirculation | 1 | 2009 | 40 | 0.080 |
Why?
|
| Antigens, Viral | 1 | 2009 | 48 | 0.080 |
Why?
|
| Gene Duplication | 1 | 2009 | 24 | 0.080 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 80 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 518 | 0.080 |
Why?
|
| Viral Load | 1 | 2011 | 348 | 0.080 |
Why?
|
| Chemokines, CXC | 1 | 2009 | 36 | 0.080 |
Why?
|
| Primates | 1 | 2009 | 39 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2009 | 93 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 1 | 2009 | 508 | 0.070 |
Why?
|
| Hela Cells | 1 | 2009 | 376 | 0.070 |
Why?
|
| Male | 3 | 2025 | 23409 | 0.070 |
Why?
|
| Cell Line | 2 | 2009 | 1410 | 0.070 |
Why?
|
| Evolution, Molecular | 1 | 2009 | 307 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 333 | 0.070 |
Why?
|
| Viral Proteins | 3 | 2003 | 190 | 0.060 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 201 | 0.060 |
Why?
|
| Pan troglodytes | 1 | 2003 | 20 | 0.050 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2002 | 22 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 37 | 0.050 |
Why?
|
| SEER Program | 1 | 2023 | 164 | 0.050 |
Why?
|
| Skin | 1 | 2023 | 187 | 0.050 |
Why?
|
| United States | 2 | 2023 | 5205 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 518 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 515 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2002 | 192 | 0.040 |
Why?
|
| Toll-Like Receptors | 1 | 2020 | 51 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2020 | 68 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2020 | 95 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2020 | 238 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 1596 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 384 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2020 | 358 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2023 | 2544 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2007 | 455 | 0.030 |
Why?
|
| Genotype | 2 | 2007 | 800 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 2157 | 0.020 |
Why?
|
| Herpesviridae Infections | 1 | 2007 | 17 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2007 | 44 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2007 | 79 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2007 | 430 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2002 | 43 | 0.010 |
Why?
|
| Virus Latency | 1 | 2002 | 49 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2002 | 74 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 49 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2002 | 154 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 224 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2002 | 321 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 983 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2002 | 403 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 526 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2002 | 972 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 592 | 0.010 |
Why?
|